 LIXTE Biotechnology Holdings Inc NASDAQ: LIXT shares are trading higher after the presentation of new data from drug combinations of LIXTEs lead clinical cancer compound, LB-100. Data were shared at the Annual Meeting of the American Association for Cancer Research AACR. 